

# Index

- 46,XX male syndrome, 113
- 47,XXY syndrome, 105
- acetylcholine, 26
- acute bacterial prostatitis (NIH Type I prostatitis), 86
- age
  - and probability of conception, 30
- albumin, 21, 51, 111
- alcohol use, 79
- alpha blockers, 31
- alternative therapies, 83
- anabolic steroids, 31
- anatomy. *See* male reproductive anatomy
- androgen deficiency, 41, 44, 51
- androgen insensitivity syndrome, 112–13
- androgen metabolism and signaling
  - chromosomal anomalies, 110–13
- androgen receptor (AR), 22–3
- androgen replacement therapy, 78–9, 80–1
- androgen-binding protein (ABP), 17
- androstenedione, 19
- anejaculation, 71–4
  - associated with previous surgery, 30
  - distinction from azoospermia, 44
- angiotensin-converting enzyme inhibitors, 79
- anterior pituitary gland, 2
- antiestrogen agents, 82
- antihypertensive medications, 79
- anti-Müllerian hormone, 4, 115
- antioxidant therapies, 82, 97–8
- antisperm antibodies, 49, 55, 92–3
  - corticosteroid therapy, 98–9
  - testing, 93–5, 127
- antisperm antibodies treatment, 98–100
  - immune suppressive therapy, 98–9
  - sperm washing with IUI or IVE, 99–100
- aromatase activity
  - testosterone to estradiol ratio, 51
- aromatase inhibitors, 82
- assisted reproductive technologies (ARTs), 131
  - sperm cryopreservation, 131–2
- asthenospermia, 55
- asymptomatic inflammatory prostatitis (NIH Type IV prostatitis), 87
- autocrine regulation of hormones, 7
- azithromycin, 86
- azoospermia, 43–4, 53–4
  - distinction from anejaculation, 44
- Barr body analysis, 104
- benign prostatic hyperplasia, 30
- bladder neck sphincter, 25
- blood–epididymis barrier, 23
- blood–testis barrier, 17, 49, 89–90, 92
- brain
  - structures involved in male reproduction, 1–2
- Bryan–Leishman staining, 93
- bulbocavernosus muscle, 3
- bulbourethral glands, 3
- caffeine, 31
- calcium channel blockers, 31, 79
- cancer therapy, 72
- caput vasoepididymostomy, 24
- CART analyses, 46, 47
- caudal genitoinguinal ligament, 4
- ceftriaxone, 86
- CFTR* gene mutations, 114–15
- chemotherapy, 31–2
- Chlamydia infection
  - role in male infertility, 79–80
- Chlamydia trachomatis*, 85, 88, 89
- cholesterol, 18
- chronic bacterial prostatitis (NIH Type II prostatitis), 86–7
- chronic pelvic pain syndrome (NIH Type III prostatitis), 87
- cimetidine, 31, 79
- claudins, 24
- clinical evaluation of the male, 29–56
  - age of both partners, 30
  - approach to evaluation, 56
  - asthenospermia, 55

- azoospermia, 53–4
- childhood illness or surgery, 33
- cryptozoospermia, 54
- effects of chemotherapy, 31–2
- effects of heat on sperm production, 32
- effects of radiotherapy, 31–2
- endocrine assays, 49–52
- family history, 33
- genetic assays, 52–3
- history form, 34
- history of infectious disease, 32–3
- nature of infertility, 30
- normozoospermia, 55
- oligoasthenospermia, 53–4
- overall evaluation, 53–6
- physical exam, 34–41
- previous children, 30
- previous exposure to toxins, 31–2
- previous surgery involving the reproductive tract, 30–1
- reasons for evaluation of the male, 29–30
- reproductive history, 30–5
- semen analysis, 41–9
- sexual history, 33–4
- teratozoospermia, 55
- thermal toxicity, 32
- time elapsed without conception, 30
- clomiphene citrate, 145, 146
  - use prior to testis biopsy, 81–2
- complementary therapies, 83
- computer-assisted semen analysis (CASA), 124
- conception
  - probability of happening, 30
- congenital bilateral absence of the vas deferens (CBAVD), 40–1, 44, 63–4
  - and *CFTR* gene mutations, 114–15
- congenital lipoid adrenal hyperplasia, 110
- congenital unilateral absence of the vas deferens, 64
- corpora cavernosa, 3
- corpus spongiosum, 3
- corticosteroid binding globulin, 21
- corticosteroid therapy, 98–9
- coxsackie B virus, 89
- cranial suspensory ligament, 4
- cryopreservation of sperm/semen, 131–2
- cryptorchidism, 33
- cryptozoospermia, 46, 54
- cytokines, 91
- de la Chapelle syndrome, 113
- dehydrotestosterone (DHT), 21
- DNA recombination errors, 116–17
- DNA repair errors, 116
- down-regulation of hormone receptors, 6
- doxycycline, 86
- ductal system
- dysgerminoma, 106, 113
- ectopic (tubal) pregnancy, 142
- efferent ductules, 3
- efferent duct–vas deferens anastomosis, 24
- ejaculation, 3, 25–6
  - emission phase, 26
  - expulsion phase, 26
- ejaculatory duct obstruction, 41, 64–5
  - evaluation, 45
- ejaculatory ducts, 3
  - structure and function, 25
- electroejaculation (EEJ), 73–4
- embryology, 4–5
  - descent of the testis, 4–5
  - development of external genitalia, 5
  - function of the *SRY* gene, 5
  - role of testosterone, 5
  - testis development, 4
  - Wolffian duct, 4
- endocrine assays
  - initial endocrine evaluation, 52
  - spermatogenesis assays, 50
  - steroidogenesis assays, 50–2
- endocrine regulation of hormones, 7
- Endtz test, 93
- Enterococcus* spp., 86, 88
- epididymis, 3
  - infections, 88–9
  - physical exam, 39
  - structure and function, 23–5, 27
- epididymitis, 88–9
- epigenetic factors in infertility, 115–16
- Escherichia coli*, 86, 88, 89
- estradiol, 9
  - testosterone to estradiol ratio, 51
- excess gene dosage concept, 105
- exogenous hormone administration
  - down regulation of hormone receptors, 6
- external genitalia
  - embryological development, 5
- feedback regulation of hormones, 5–6
- female infertility, 134–51
  - anovulation, 136–9
  - approach to evaluation, 134–5
  - causes of infertility, 136
  - cervical factor infertility, 145
  - definition of infertility, 135

## 154 Index

- female infertility (cont.)
  - diminished ovarian reserve, 140–1
  - ectopic (tubal) pregnancy, 142
  - elevated prolactin level, 138–9
  - endometrial polyps, 144
  - endometriosis, 143–4
  - fallopian tube disease or damage, 141–3
  - fallopian tube patency, 141–3
  - fibroids (myomas, leiomyomas), 144
  - hypothalamic amenorrhea, 139
  - inadequate endometrial development, 145
  - luteal phase defect, 145
  - normal ovulatory cycle, 136
  - obesity-related anovulation, 139
  - ovarian dysfunction, 136–41
  - ovarian failure, 139
  - ovarian insufficiency, 140–1
  - pelvic adhesive disease, 141–3
  - polycystic ovarian syndrome (PCOS), 138
  - premature menopause, 139
  - sexual dysfunction, 136
  - stress-induced amenorrhea, 139
  - summary of the infertility evaluation, 145
  - testing for ovulation, 136–8
  - treatments, 146–51
  - unexplained infertility, 146
  - uterine factor infertility, 144
- female infertility treatment, 146–51
  - clomiphene citrate, 146
  - gonadotropin injections, 146–7
  - in vitro fertilization (IVF), 148–50
  - intrauterine insemination (IUI), 147
  - lifestyle recommendations for improved fertility, 150–1
  - ovulation induction medications (injectable), 146–7
  - ovulation induction medications (oral), 146
  - pregnancy rates from different treatments, 148
- fertilization
  - sperm–egg interaction, 26–7
- follicle-stimulating hormone (FSH), 2
  - regulation by GnRH, 8
  - regulation of secretion, 9–10
  - role in spermatogenesis, 17–18
- free radicals. *See* reactive oxygen species (ROS)
- fructose level of semen, 48
- genetic assays
  - karyotype, 52–3
  - Y chromosomal microdeletion assay, 52–3
- genetics, 103–18
  - 46,XX male syndrome, 113
  - 47,XXY syndrome, 105
  - androgen insensitivity syndrome, 112–13
  - aneuploidy, 103–6
  - anomalies of androgen metabolism and signaling, 110–13
  - CFTR* gene mutations, 114–15
  - chromosomal translocation or inversion, 106
  - de la Chapelle syndrome, 113
  - DNA recombination errors, 116–17
  - DNA repair errors, 116
  - epigenetic factors in infertility, 115–16
  - excess gene dosage concept, 105
  - hypogonadotropic hypogonadism without anosmia, 110
  - idiopathic hypogonadotropic hypogonadism (IHH), 110
  - Jacob's syndrome, 105
  - Kallmann syndrome, 109–10
  - Kennedy's syndrome, 113
  - Klinefelter syndrome, 103–5
  - mitochondrial DNA anomalies, 117–18
  - mixed gonadal dysgenesis (45,X/46,XY), 105–6
  - numerical chromosomal abnormalities, 103–6
  - persistent Müllerian duct syndrome, 115
  - Reifenstein's syndrome, 113
  - ring Y chromosome, 106
  - Robertsonian translocation, 106
  - SRY* gene mutation, 114
  - X chromosomal anomalies, 109–10
  - X-linked spinal and bulbar muscular atrophy, 113
  - Y chromosomal anomalies, 106–9
- genitourinary infections, 79–80
- glands of Littré, 3
- glans, 3
- gonadal dysgenesis, 112
- gonadoblastoma, 106
- gonadotrophin-releasing hormone (GnRH), 2
  - autocrine regulation, 8
  - endocrine regulation, 9
  - paracrine control, 9
  - regulation of LH and FSH, 8
  - regulation of secretion, 7–9
  - role in the HPG axis, 7–9
- gonadotrophins, 82
  - regulation of secretion, 9–10
  - See also* follicle-stimulating hormone (FSH), luteinizing hormone (LH).
- gonadotrophs, 2
- gonococcal urethritis, 85–6
- growth hormone (GH), 12
- gubernaculum, 4
- gynecomastia, 37

- hematospermia, 87
- hernia
  - check for presence of, 41
- herniorrhaphy, 31, 33
- history form, 34
- homeostasis
  - hormone secretion control, 5–6
- hormonal control
  - spermatogenesis, 17–18
- hormone secretion control, 5–7
  - autocrine regulation, 7
  - desensitization, 7
  - down regulation of hormone receptors, 6
  - effects of exogenous hormone administration, 6
  - endocrine regulation, 7
  - feedback regulation, 5–6
  - maintaining homeostasis, 5–6
  - negative feedback inhibition, 5–6
  - paracrine regulation, 7
  - up regulation of hormone receptors, 6
- hormones
  - hypothalamus–pituitary–gonadal (HPG) axis, 7–12
- human chorionic gonadotropin (hCG), 4
- hydrocele, 39
- hyperprolactinemia management, 81
- hypogastric nerves, 26
- hypogonadotropic hypogonadism, 31
  - management, 80
- hypogonadotropic hypogonadism without anosmia, 110
- hypo-osmotic swelling test, 47
- hypophyseal portal system, 2
- hypospadias, 33, 41
- hypothalamus
  - role in male reproduction, 2
- hypothalamus–pituitary–gonadal (HPG) axis, 5
- hypothalamus–pituitary–gonadal (HPG) axis
  - hormones, 7–12
    - FSH, 9–10
    - GnRH, 7–9
    - gonadotrophins, 9–10
    - growth hormone (GH), 12
    - inhibin, 11–12
    - insulin-like growth factor-1 (IGF-1), 12
    - interleukin-1 $\alpha$  (IL-1 $\alpha$ ), 12
    - LH, 9–10
    - testicular factors, 10–12
    - testosterone, 10–11
    - transforming growth factor beta (TGF $\beta$ ), 12
- idiopathic hypogonadotropic hypogonadism (IHH), 110
- imipramine, 73
- immotile cilia syndrome, 54
- immunology, 84–100
  - antisperm antibodies, 92–3
  - antisperm antibodies diagnostic testing, 93–5
  - antisperm antibodies treatment, 98–100
  - cytokines, 91
  - effects of nitric oxide (NO), 92
  - epididymitis, 88–9
  - infections of the reproductive tract, 84–9
  - leukocytospermia, 89–91, 91–2
  - leukocytospermia diagnostic testing, 93
  - leukocytospermia treatment, 95–6
  - orchitis, 89
  - oxidative stress, 91–2
  - pro-inflammatory cytokines, 91
  - prostatitis, 86–7
  - reactive oxygen species (ROS), 91–2
  - reactive oxygen species (ROS) diagnostic testing, 93
  - reactive oxygen species (ROS) treatment, 96–8
  - seminal vesiculitis, 87–8
  - sperm washing, 99–100
  - urethritis (gonococcal and non-gonococcal), 85–6
  - vaginitis, 88
- in vitro fertilization (IVF), 29, 47, 48, 54, 62, 139, 142, 146, 148–50
  - cryopreserved embryo transfer, 150
  - donor eggs or embryos, 150
  - egg freezing, 150
  - outcomes, 148
  - preimplantation genetic diagnosis (PGD), 148
  - preimplantation genetic screening (PGS), 148
  - sperm washing, 99–100
  - steps in the IVF process, 149–8
  - surrogacy, 150
  - See also* IVF/ICSI.
- infections of the reproductive tract, 84–9
  - epididymis, 88–9
  - management of genitourinary infections, 79–80
  - orchitis, 89
  - prostate infections, 86–7
  - seminal vesicles, 87–8
  - urethritis, 85–6
  - vas deferens, 88
- infectious disease
  - history of, 32–3
- infertile couple
  - approach to evaluation, 134–5
- infertility
  - approach to male infertility, 1

## 156 Index

- infertility (cont.)
  - as a disease of the reproductive system, 1
  - definition, 1, 30
- infertility treatment
  - considerations when offering treatment, 77–8
- inhibin
  - secretion and control, 11–12
- insulin-like growth factor-1 (IGF-1), 12
- interleukin-1 $\alpha$  (IL-1 $\alpha$ ), 12
- intracytoplasmic sperm injection (ICSI), 29, 47, 48, 54, 62, 103, 128
  - sperm cryopreservation, 131–2
  - sperm washing, 130–1
  - See also* IVF/ICSI.
- intrauterine insemination (IUI)
  - female infertility treatment, 147
  - sperm cryopreservation, 131–2
  - sperm washing, 99–100, 131
- ischio-cavernosus muscles, 3
- IVF/ICSI, 100
  - sperm cryopreservation, 131–2
  - sperm washing, 130–1
  - See also* in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI).
- Jacob's syndrome, 105
- Kallmann syndrome, 51, 80, 109–10
- Kartagener syndrome, 55
- karyotype analysis, 52–3, 69, 104
- Kennedy's syndrome, 113
- Klebsiella* spp., 86, 89
- Klinefelter syndrome, 37, 69, 103–5
- Kruger morphology, 47–8
- L-carnitine, 82
- leukocytes
  - presence in semen, 48–9
- leukocytospermia, 89–91, 92
  - diagnostic testing, 93
  - reactive oxygen species (ROS) and oxidative stress, 91–2
- leukocytospermia treatment, 95–6
  - antibiotics, 95–6
  - antihistamines, 96
  - anti-inflammatory agents, 96
- Leydig cells, 3, 5
  - development, 4
  - dysfunction prior to puberty, 37
  - testosterone biosynthesis, 18–21
- luteinizing hormone (LH), 2
  - regulation by GnRH, 8
  - regulation of secretion, 9–10
  - role in spermatogenesis, 17–18
- male pseudohermaphroditism, 110
- male reproductive anatomy, 1–4
  - anterior pituitary gland, 2
  - brain structures, 1–2
  - bulbourethral glands, 3
  - components of seminal fluid, 3
  - ejaculatory ducts, 3
  - embryology, 4–5
  - epididymis, 3
  - glands of Littre, 3
  - gonadotrophs, 2
  - hypophyseal portal system, 2
  - hypothalamus, 2
  - penis, 3–4
  - prostate, 3
  - seminal vesicles, 3
  - testicular blood supply, 2–3
  - testis, 3
  - vas deferens, 3
- male reproductive ductal system, 23–5
  - ejaculatory ducts, 25
  - epididymis, 23–5
  - prostate, 25
  - seminal vesicles, 25
  - vas deferens, 25
- marijuana, 31, 79
- Meacham's maxim, 40
- medications and substances to avoid, 78–9
- mesh herniorrhaphy, 31
- methylprednisolone, 98
- mitochondrial DNA anomalies, 117–18
- mixed gonadal dysgenesis (45,X/46,XY), 105–6
- monoclonal antibodies, 93
  - testing for seminal leukocytes, 93
- Müllerian duct
  - persistent Müllerian duct syndrome, 115
- mumps, 32, 33
- mumps orchitis, 89
- Mycoplasma* spp., 85
- necropermia, 54
- negative feedback regulation of hormones, 5–6
- Neisseria gonorrhoeae*, 85, 88, 89
- neuropeptide Y, 9
- neurotensin, 9
- nicotine, 31
- nitric oxide (NO), 26, 92
- non-gonococcal urethritis, 85–6
- non-obstructive azoospermia, 43–4
  - surgical sperm retrieval, 71

- non-surgical therapy, 77–83  
   androgen replacement therapy, 78–9, 80–1  
   avoiding supplemental testosterone therapy, 78–9  
   choice of undergarments, 82  
   complementary and alternative therapies, 83  
   considerations when offering treatment, 77–8  
   management of chlamydia infection, 79–80  
   management of genitourinary infections, 79–80  
   management of hyperprolactinemia, 81  
   management of hypogonadotropic hypogonadism, 80  
   management of Kallmann syndrome, 80  
   medications and substances to avoid, 78–9  
   range of empiric therapies, 83  
   strategies to increase testosterone levels, 80–1  
   use of clomiphene citrate prior to testis biopsy, 81–2  
 norepinephrine, 9, 26  
 normozoospermia, 55
- obesity-related anovulation, 139  
 obstructive azoospermia, 43–4, 62–3  
 occludin, 24  
 oligoasthenospermia, 53–4  
 oligospermia, 46  
 Online Mendelian Inheritance in Man (OMIM) project, 118  
 opioid narcotic use, 31  
 orchidopexy, 33  
 orchitis, 89  
   bacterial, 89  
   paramyxovirus (mumps), 89  
 oxidative stress, 91–2  
 oxytocin, 26
- pampiniform plexus, 3  
   varicocele, 39–40  
 paracrine regulation of hormones, 7  
 paramyxovirus (mumps) orchitis, 89  
 penile vibratory stimulation (PVS), 73  
 penis  
   anatomy, 3–4  
   blood supply, 3–4  
   embryological development, 5  
   physical exam, 41  
   physiology, 3–4  
 peroxidase (Endtz) test, 93  
 persistent Müllerian duct syndrome, 115  
 Peyronie's disease, 41  
 pH of semen, 48  
 physical exam, 34–41  
   body habitus, 37  
   check for presence of hernia, 41  
   epididymis, 39  
   external inguinal ring, 41  
   gynecomastia, 37  
   hydrocele, 39  
   Klinefelter syndrome, 37  
   phallus, 41  
   prostate, 41  
   putting your patient at ease, 34–7  
   seminal vesicles, 41  
   spermatic cord, 39–41  
   spermatocele, 39  
   testis, 37–9  
   varicocele, 39–40  
   vas deferens, 40–1  
 placental chorionic gonadotropins, 4  
 polycystic ovarian syndrome (PCOS), 138  
 post-ejaculatory urinalysis (PEU), 44–5  
 Prader orchidometer, 38  
 prednisone, 98  
 pregnenolone, 18  
 pro-inflammatory cytokines, 91  
 prolactin level, 52  
 prostate, 3, 25  
   hypoplasia, 44  
   physical exam, 41  
 prostate infections, 32, 86–7  
   acute bacterial prostatitis (NIH Type I prostatitis), 86  
   asymptomatic inflammatory prostatitis (NIH Type IV prostatitis), 87  
   chronic bacterial prostatitis (NIH Type II prostatitis), 86–7  
   chronic pelvic pain syndrome (NIH Type III prostatitis), 87  
 prostatectomy, 30  
   *Proteus* spp., 86  
   pseudoephedrine, 73  
   *Pseudomonas* spp., 86, 89  
   pseudosarcomatous proliferative funiculitis, 88  
   pseudovaginal perineoscrotal hypospadias, 111  
   pudendal nerve, 3
- radical prostatectomy, 30  
 radiotherapy, 31–2  
 reactive oxygen species (ROS), 91–2  
   diagnostic testing, 93  
   semen analysis, 127  
 reactive oxygen species (ROS) treatment, 96–8  
   antioxidant therapies, 97–8  
   lifestyle modification, 97  
 recreational drugs, 79  
 reflux epididymitis, 88

**158** Index

- regression to the mean, 43
- Reifenstein's syndrome, 113
- reproductive history, 30–5
  - childhood illness or surgery, 33
  - family history, 33
  - infectious disease, 32–3
  - sexual history, 33–4
  - spermatotoxicity, 31–2
- rete testis, 3
- retrograde ejaculation, 30, 44–5
- retroperitoneal lymph node dissection, 30, 71
- ring Y chromosome, 106
- Robertsonian translocation, 106
- Seager orchidometer, 38
- semen analysis, 41–9, 121–8
  - anejaculation, 44
  - antisperm antibodies, 49, 127
  - azoospermia, 43–4
  - bulk semen analysis, 41–3
  - CART analyses, 42
  - collection method, 122–3
  - computer-assisted semen analysis (CASA), 124
  - cryptozoospermia, 46
  - effects of regression to the mean, 43
  - ejaculatory duct obstruction, 45
  - fructose levels, 48
  - hypo-osmotic swelling test, 47
  - information from, 121
  - Kruger morphology, 47–8
  - laboratory analysis, 123–4
  - leukocytes, 48–9
  - multiple testing, 122
  - non-obstructive azoospermia, 43–4
  - obstructive azoospermia, 43–4
  - oligospermia, 46
  - period of abstinence, 122–3
  - pH, 48
  - post-ejaculatory urinalysis (PEU), 44–5
  - reactive oxygen species (ROS), 127
  - retrograde ejaculation, 44–5
  - semen character, 44
  - semen volume, 44–6
  - seminal hypovolemia, 44–6
  - sperm concentration, 46
  - sperm density, 46
  - sperm morphology, 47–8, 124–5
  - sperm motility, 46–7
  - sperm staining test, 47
  - sperm vitality, 47
  - strict morphology, 47–8
  - testing procedure, 121–2
  - tests of male fertility potential, 125–8
  - total motile count (TMC), 47
  - total sperm number, 46
  - transportation of samples, 122–3
  - Tygerberg morphology, 47–8
  - WHO criteria for assessing male fertility potential, 125–7
- semen cryopreservation, 131–2
- semen processing
  - for IUI and ARTs, 128–31
- seminal fluid
  - components, 3
- seminal hypovolemia, 44–6
- seminal vesicle aspiration (SVA), 64–5
- seminal vesicles, 3, 25
  - hypoplasia, 44
  - infection or inflammation, 87–8
  - physical exam, 41
- seminal vesiculitis, 87–8
- seminiferous tubules, 3
- Sertoli cells, 3
  - blood–testis barrier, 17
  - development, 4
  - role in spermatogenesis, 16–17
- Sertoli-only syndrome, 106, 109
- sex hormone binding globulin (SHBG), 21–2, 51, 111
- sexual history, 33–4
- sexual response cycle, 25
- situs inversus, 55
- sperm banking, 131–2
- sperm concentration, 46
- sperm cryopreservation, 72, 131–2
- sperm density, 46
- sperm morphology, 124–5
- sperm processing
  - for IUI and ARTs, 131
- sperm washing, 128–31
- spermatic cord
  - physical exam, 39–41
- spermatid formation, 15
- spermatocoele, 39
- spermatogenesis, 12–18
  - endocrine assays, 50
  - formation of preleptotene spermatocytes, 14–15
  - formation of spermatids, 15
  - hormonal control, 17–18
  - role of FSH, 17–18
  - role of LH, 17–18
  - role of Sertoli cells, 16–17
  - spermatogenic cycles, 12–16
  - spermatogenic wave, 13

- spermatogonial proliferation, differentiation and division, 14–15
- spermiation, 16
- spermiogenesis, 15–16
- spermatogenic dysfunction, 69–71
- spermatogenic wave, 13
- spermatotoxicity
  - history of, 31–2
- sperm–egg interaction, 26–7
  - acrosomal exocytosis, 27
- spermiation, 16
- spermiogenesis, 15–16
- spinal cord injuries (SCI), 73
- spironolactone, 79
- SRY (sex-determining region of the Y chromosome), 4
- SRY gene, 5
- SRY gene mutation, 113
- Staphylococcus* spp., 89
- steroidogenesis, 18–23
  - androgen receptor (AR), 22–3
  - biosynthesis, 18–21
  - endocrine assays, 50–2
  - mechanism of androgen action, 22–3
  - prolactin level, 52
  - secretion, 21
  - testosterone biosynthesis, 18–21
  - testosterone levels, 50–2
  - testosterone secretion, 21
  - testosterone to estradiol ratio, 51
  - testosterone transport, 21–2
- steroidogenic acute regulatory protein (StAR), 18, 110
- Streptococcus* spp., 89
- strict criteria for sperm morphology, 47–8, 124–5
- teratozoospermia, 55
- substances and medications to avoid, 78–9
- surgery
  - history of surgery involving the reproductive tract, 30–1
- surgical conditions and techniques, 58–75
  - anejaculation, 71–4
  - congenital bilateral absence of the vas deferens (CBAVD), 63–4
  - congenital unilateral absence of the vas deferens, 64
  - ejaculatory duct obstruction, 64–5
  - electroejaculation (EEJ), 73–4
  - non-obstructive azoospermia, 69–71
  - obstructive azoospermia, 62–3
  - seminal vesicle aspiration (SVA), 64–5
- spermatogenic dysfunction, 69–71
- surgical sperm retrieval in NOA, 71
- testicular sperm extraction (TESE)
  - techniques, 71
- transrectal electroejaculation (EEJ), 73–4
- transurethral resection of the ejaculatory duct (TURED), 65
- varicocele and varicolectomy, 58–62
- vasal occlusion, 65–9
- vasectomy, 74–5
- vasectomy reversal, 65–9
- Swyer's syndrome, 112
- teratozoospermia, 55
- testicular factors
  - hypothalamus–pituitary–gonadal (HPG) axis, 10–12
- testicular sperm extraction (TESE) techniques, 71
- testicular torsion, 33
- testis
  - blood supply, 2–3
  - descent in the embryo, 4–5
  - embryological development, 4
  - examination, 37–9
  - inguinoscrotal stage of descent, 5
  - orchitis, 89
  - transabdominal stage of descent, 5
- testis anatomy, 3
  - efferent ductules, 3
  - rete testis, 3
  - seminiferous tubules, 3
  - Sertoli cells, 3
  - tunica albuginea, 3
- testis biopsy
  - use of clomiphene citrate prior to, 81–2
- testis cancer, 30
  - effects of chemotherapy and radiotherapy, 31–2
- testosterone
  - aromatization to estradiol, 9
  - binding to plasma proteins, 21–2
  - biosynthesis, 18–21
  - effects of supplemental testosterone, 78–9
  - mechanism of action, 22–3
  - negative feedback control of secretion, 5–6
  - production in the male embryo, 4
  - role in embryological development, 5
  - secretion, 21
  - secretion and control, 10–11
  - steroidogenesis assays, 50–2
  - strategies to increase testosterone levels, 80–1
  - transport, 21–2



## 160 Index

- testosterone to estradiol ratio, 51
- thermal effects on sperm production, 32
- tobacco, 79
- transforming growth factor beta (TGF $\beta$ ), 12
- transrectal electroejaculation (EEJ), 73–4
- transurethral resection of the ejaculatory duct (TURED), 65
- Trichomonas vaginalis*, 85
- tuberculosis, 32
- tubuloalveolar glands, 3
- tunica albuginea, 3
- Tygerberg morphology, 47–8
- undergarments
  - choice of, 82
- up regulation of hormone receptors, 6
- urethritis, 85–6
  - gonococcal, 85–6
  - non-gonococcal, 85–6
  - transmission to female partner, 85
- varicocele, 39–40
  - and varicocelectomy, 58–62
- varicocelectomy, 58–62
- vas deferens, 3
  - absence of, 40–1
  - infection and inflammation, 88
  - physical exam, 40–1
  - structure and function, 25
  - See also* congenital bilateral absence of the vas deferens (CBAVD).
- vasal atresia, 88
- vasal occlusion, 65–9
- vasal stenosis, 88
- vasectomy, 40, 74–5
  - reversal, 65–9
- vasitis, 88
- vasoactive intestinal peptide (VIP), 26
- Wolffian duct, 4
- World Health Organization (WHO)
  - criteria for assessing male fertility potential, 125–7
  - definition of infertility, 1
- X chromosome
  - anomalies, 109–10
- X-linked spinal and bulbar muscular atrophy, 113
- Y chromosome
  - anomalies, 106–9
  - azoospermia factor area (AZF), 106–9
  - ring Y chromosome, 106
- Y chromosome microdeletions test, 52–3, 69–71